In silico and in vitro comparative activity of novel experimental derivatives against Leishmania major and Leishmania infantum promastigotes

Experimental Parasitology

Volumn 135, Issue 2, 2013, Pages 208-216

  Khademvatan, Shahram ^a   Adibpour, Neda ^a   Eskandari, Alborz ^a   Rezaee, Saeed ^a   Hashemitabar, Mahmoud ^a   Rahim, Fakher ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antileishmanial activity; Biurets; In silico; In vitro; MTT

Indexed keywords

MEGLUMINE ANTIMONATE; PTERIDINE DERIVATIVE;

ARTICLE; CELL STRUCTURE; COLORIMETRY; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); GROWTH INHIBITION; IC 50; IN VITRO STUDY; KINETOPLASTIDA; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; PROMASTIGOTE;

ANTILEISHMANIAL ACTIVITY; BIURETS; IN SILICO; IN VITRO; MTT;

ANTIPROTOZOAL AGENTS; BIURET; COLORIMETRY; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; PHYLOGENY;

EID: 84882608082     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2013.07.004     Document Type: Article

References (53)

1. Abdul-Ghani R., Al-Mekhlafi A.M., Alabsi M.S. Microbial control of malaria: biological warfare against the parasite and its vector. Acta Trop. 2012, 121(2):71-84.
2. Adibpour N., Rahim F., Rezaeei S., Khalaj A., Ebrahimi A. In silico designing selective inhibitor of drugs, medicinal plants compounds and experimental ligands for pteridine reductase targeting visceral leishmaniasis. Afr. J. Microbiol. Res. 2012, 6(5):917-926.
3. Alizadeh R., Hooshyar H., Bandehpor M., Arbabi M., Kazemi F., Talari A., et al. Detection of drug resistance gene in cutaneous leishmaniasis by PCR in some endemic areas of iran. Iran. Red Crescent Med. J. 2011, 13(12):863-867.
4. Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop. Med. Int. Health 2001, 6(11):928-934.
5. Cavazzuti A., Paglietti G., Hunter W.N., Gamarro F., Piras S., Loriga M., et al. Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development. Proc. Natl. Acad. Sci. USA 2008, 105(5):1448-1453.
6. Chakravarty J., Sundar S. Drug resistance in leishmaniasis. J. Glob. Infect. Dis. 2010, 2(2):167-176.
7. Chandra S., Ruhela D., Deb A., Vishwakarma R.A. Glycobiology of the Leishmania parasite and emerging targets for antileishmanial drug discovery. Expert Opin. Ther. Targets 2010, 14(7):739-757.
8. Chawla B., Madhubala R. Drug targets in Leishmania. J. Parasit. Dis. 2010, 34(1):1-13.
9. Colovos C., Yeates T.O. Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci. 1993, 2(9):1511-1519.
10. Combet C., Jambon M., Deleage G., Geourjon C. Geno3D: automatic comparative molecular modelling of protein. Bioinformatics 2002, 18(1):213-214.
11. Control of the Leishmaniases Report of a WHO Expert Committee. World Health Organ. Tech. Rep. Ser. 1990, 793:1-158.
12. Croft S.L. Monitoring drug resistance in leishmaniasis. Trop. Med. Int. Health 2001, 6(11):899-905.
13. Croft S.L., Sundar S., Fairlamb A.H. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 2006, 19(1):111-126.
14. Davis A.J., Kedzierski L. Recent advances in antileishmanial drug development. Curr. Opin. Investig. Drugs 2005, 6(2):163-169.
15. Drummelsmith J., Brochu V., Girard I., Messier N., Ouellette M. Proteome mapping of the protozoan parasite Leishmania and application to the study of drug targets and resistance mechanisms. Mol. Cell. Proteomics 2003, 2(3):146-155.
16. Ferrari S., Morandi F., Motiejunas D., Nerini E., Henrich S., Luciani R., et al. Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase. J. Med. Chem. 2011, 54(1):211-221.
17. Fouladdel S., Khalaj A., Adibpour N., Azizi E. Synthesis and cytotoxicity of some biurets against human breast cancer T47D cell line. Bioorg. Med. Chem. Lett. 2010, 20(19):5772-5775.
18. Fuertes M.A., Nguewa P.A., Castilla J., Alonso C., Perez J.M. Anticancer compounds as leishmanicidal drugs: challenges in chemotherapy and future perspectives. Curr. Med. Chem. 2008, 15(5):433-439.
19. Gangwar S., Baig M.S., Shah P., Biswas S., Batra S., Siddiqi M.I., et al. Identification of novel inhibitors of dipeptidylcarboxypeptidase of Leishmania donovani via ligand-based virtual screening and biological evaluation. Chem. Biol. Drug Des. 2012, 79(2):149-156.
20. Grogl M., Thomason T.N., Franke E.D. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am. J. Trop. Med. Hyg. 1992, 47(1):117-126.
21. Kaur J., Kumar P., Tyagi S., Pathak R., Batra S., Singh P., et al. In silico screening, structure-activity relationship, and biologics evaluation of selective pteridine reductase inhibitors targeting visceral leishmaniasis. Antimicrob. Agents Chemother. 2011, 55(2):659-666.
22. Kaur J., Tiwari R., Kumar A., Singh N. Bioinformatic analysis of leishmania donovani long-chain fatty acid-CoA ligase as a novel drug target. Mol. Biol. Int. 2011, 2011:278051.
23. Kedzierski L., Sakthianandeswaren A., Curtis J.M., Andrews P.C., Junk P.C., Kedzierska K. Leishmaniasis: current treatment and prospects for new drugs and vaccines. Curr. Med. Chem. 2009, 16(5):599-614.
24. Khademvatan S., Gharavi M.J., Rahim F., Saki J. Miltefosine-induced apoptotic cell death on Leishmania major and L. tropica strains. Korean J. Parasitol. 2011, 49(1):17-23.
25. Kumar P., Kumar A., Verma S.S., Dwivedi N., Singh N., Siddiqi M.I., et al. Leishmania donovani pteridine reductase 1: biochemical properties and structure-modeling studies. Exp. Parasitol. 2008, 120(1):73-79.
26. Kuntal B.K., Aparoy P., Reddanna P. EasyModeller: a graphical interface to MODELLER. BMC Res Notes 2010, 3:226.
27. Loiseau P.M., Gupta S., Verma A., Srivastava S., Puri S.K., Sliman F., et al. In vitro activities of new 2-substituted quinolines against Leishmania donovani. Antimicrob. Agents Chemother. 2011, 55(4):1777-1780.
28. Maltezou H.C. Drug resistance in visceral leishmaniasis. J. Biomed. Biotechnol. 2010, 2010:617521.
29. McColm A.A., McHardy N. Evaluation of a range of antimicrobial agents against the parasitic protozoa, Plasmodium falciparum, Babesia rodhaini and Theileria parva in vitro. Ann. Trop. Med. Parasitol. 1984, 78(4):345-354.
30. Monte-Alegre A., Ouaissi A., Sereno D. Leishmania amastigotes as targets for drug screening. Kinetoplastid Biol. Dis. 2006, 5:6.
31. Morais T.R., Romoff P., Favero O.A., Reimao J.Q., Lourenco W.C., Tempone A.G., et al. Anti-malarial, anti-trypanosomal, and anti-leishmanial activities of jacaranone isolated from Pentacalia desiderabilis (Vell.) Cuatrec. (Asteraceae). Parasitol. Res. 2012, 110(1):95-101.
32. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65(1-2):55-63.
33. Naula C., Parsons M., Mottram J.C. Protein kinases as drug targets in trypanosomes and Leishmania. Biochim. Biophys. Acta 2005, 1754(1-2):151-159.
34. Polonio T., Efferth T. Leishmaniasis: drug resistance and natural products (Review). Int. J. Mol. Med. 2008, 22(3):277-286.
35. Pomel S., Rodrigo J., Hendra F., Cave C., Loiseau P.M. In silico analysis of a therapeutic target in Leishmania infantum: the guanosine-diphospho-d-mannose pyrophosphorylase. Parasite 2012, 19(1):63-70.
36. Poorrajab F., Ardestani S.K., Foroumadi A., Emami S., Kariminia A., Behrouzi-Fardmoghadam M., et al. Selective leishmanicidal effect of 1,3,4-thiadiazole derivatives and possible mechanism of action against Leishmania species. Exp. Parasitol. 2009, 121(4):323-330.
37. Postigo J.A. Leishmaniasis in the World Health Organization Eastern Mediterranean Region. Int. J. Antimicrob. Agents 2010, 36(Suppl. 1):S62-S65.
38. Pruitt K.D., Tatusova T., Maglott D.R. NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res. 2007, 35:D61-D65. (Database issue).
39. Pruitt K.D., Tatusova T., Klimke W., Maglott D.R. NCBI reference sequences: current status, policy and new initiatives. Nucleic Acids Res. 2009, 37:D32-D36. (Database issue).
40. Rahim F. An in silico development of selective inhibitor for histamine receptors. Biotechnology 2010, 9:157-163.
41. Reithinger R., Dujardin J.C., Louzir H., Pirmez C., Alexander B., Brooker S. Cutaneous leishmaniasis. Lancet Infect Dis. 2007, 7(9):581-596.
42. Ropelewski A.J., Nicholas H.B., Gonzalez Mendez R.R. MPI-PHYLIP: parallelizing computationally intensive phylogenetic analysis routines for the analysis of large protein families. PLoS One 2010, 5(11):e13999.
43. Saha P., Mukhopadhyay D., Chatterjee M. Immunomodulation by chemotherapeutic agents against Leishmaniasis. Int. Immunopharmacol. 2011, 11(11):1668-1679.
44. Schwede T., Kopp J., Guex N., Peitsch M.C. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res. 2003, 31(13):3381-3385.
45. Singh G., Jayanarayan K.G., Dey C.S. Arsenite resistance in Leishmania and possible drug targets. Adv. Exp. Med. Biol. 2008, 625:1-8.
46. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health 2001, 6(11):849-854.
47. Thakur C.P., Sinha G.P., Pandey A.K., Kumar N., Kumar P., Hassan S.M., et al. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases. Ann. Trop. Med. Parasitol. 1998, 92(5):561-569.
48. Trott O., Olson A.J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010, 31(2):455-461.
49. Van Assche T., Deschacht M., da Luz R.A., Maes L., Cos P. Leishmania-macrophage interactions: insights into the redox biology. Free Radic. Biol. Med. 2011, 51(2):337-351.
50. Verma N.K., Dey C.S. Possible mechanism of miltefosine-mediated death of Leishmania donovani. Antimicrob. Agents Chemother. 2004, 48(8):3010-3015.
51. Verma A., Srivastava S., Sane S.A., Marrapu V.K., Srinivas N., Yadav M., et al. Antileishmanial activity of benzocycloalkyl azole oximino ethers: the conformationally constraint analogues of oxiconazole. Acta Trop. 2011, 117(2):157-160.
52. W.H.O. Control of the leishmaniases. Geneva; 2010.
53. Wise L.N., Ueti M.W., Kappmeyer L.S., Hines M.T., White S.N., Davis W., et al. In vitro activity of ponazuril against Theileria equi. Vet. Parasitol. 2012, 185(2-4):282-285.